32 results about "Technetium-99" patented technology

An accelerator based systems are disclosed for the generation of isotopes, such as molybdenum-98 (“99Mo”) and metastable technetium-99 (“99mTc”) from molybdenum-98 (“98Mo”). Multilayer targets are disclosed for use in the system and other systems to generate 99mTc and 98Mo, and other isotopes. In one example a multilayer target comprises a first, inner target of 98Mo surrounded, at least in part, by a separate, second outer layer of 98Mo. In another example, a first target layer of molybdenum-100 is surrounded, at least in part, by a second target layer of 98Mo. In another example, a first inner target comprises a Bremsstrahlung target material surrounded, at least in part, by a second target layer of molybdenum-100, surrounded, at least in part, by a third target layer of 98Mo.

Systems and methods for separation or isolation of technetium radioisotopes from aqueous solutions of radioactive or non-radioactive molybdate salts using a polyalkyl glycol-based cross-linked polyether polymer. Some embodiments can be used for the effective purification of radioactive technetium-99m produced from low specific activity 99Mo.

A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [99mTc(N)(PNP)(XY)]+. In this formula, 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand as described in the specification. The compound of the formula is markedly accumulated in heart and adrenal glands and hence is used for radiodiagnostic imaging of heart and adrenal glands.

The invention relates to a novel technetium-99m-labeled higher fatty acid derivative. The derivative is characterized in that tricarbonyl technetium coordinates with higher fatty acid cyclopentadiene, and the fatty acid connected with cyclopentadiene comprises carbonyl group and unsaturated cyclic group. The derivative can be used as a myocardium imaging agent, and can solve the defects of high liver background or high blood background existing in the prior art when the existing technetium-99mm-labeled higher fatty acid derivative is applied to the myocardium imaging agent; and therefore, the novel technetium-99m-labeled higher fatty acid derivative which has low liver background and low blood background, and can be clinically used as the myocardium imaging agent is provided.

The invention relates to a method for analyzing the content of technetium-99 in soil. The method includes the following steps that sample preprocessing operations such as drying, smashing and screening are performed, operations, for transferring the technetium-99 into a solution, such as weighing, ashing and soaking are performed, the technetium-99 is separated, enriched and purified, and radioactive measurement is performed on the technetium-99. According to the method, the technetium-99 is separated, enriched and purified with a special effect solid-phase extraction disk method, separation, enriching and purification can be completed within half an hour, and the special effect solid-phase extraction disk method is far easier, more convenient and faster than a traditional chromatographic method or a precipitation method; a solid-phase extraction disk enriched with the technetium-99 can be directly used for radioactive measurement, the situation that after separation is performed with other methods, a measurement source is prepared by drying by distillation and redissolving is avoided, in other words, the step for preparing the radioactive measurement source is omitted, operation is easier and more convenient, and workloads of analysts are reduced.

The invention discloses a medicine box for preparing technetium-99m (99mTc) labeled DTPA-LSA (99mTc-DTPA-LSA), a preparation method and application thereof. The medicine box is prepared by the method as follows: dissolving DTPA-LSA ligand in nitrogen-filled secondary water; adding buffer solution; mixing well; adding a reducing agent in a weight ratio of the reducing agent to the ligand of 1:10-800; performing sterile filtration on solution after dissolution is completely over; and putting the obtained product into containers separately. In the aspect of preparing 99mTc-DTPA-LSA, the medicinebox has the advantages of use convenience, high labeling rate, good biological properties of prepared 99mTc-DTPA-LSA, low use cost and the like, and is beneficial to extensive clinical application. 99mTc-DTPA-LSA complex prepared by utilizing the medicine box can be sued as a novel liver imaging agent applied in the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine.

The invention relates to a kit which is used for preparing <99m> Tc-GSA. Weight ratio of a reducing agent of the kit: a GSA ligand: adjuvant is 0.01-0.2:2-8:0.05-2; the reducing agent is a routine chemical reagent which can reduce <99m> Tc <7+> (<99m> TcO4<->) to <99m> Tc <5+>. The invention also relates to a preparation method of the kit. In the preparation of <99m> Tc-GSA, the kit of the invention has the advantages of simple method, high mark rate, excellent biological properties of prepared <99m> Tc-GSA and low use cost, and facilitates wide clinical application.